text_1: FDA advisory panel backs Merck's blood clot-preventing drug.
text_2: Merck & Co Inc’s experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.